R&D Centers
R&D People
Projects in Progress
The Global Innovative Product 莱特灵?/Ryaltris? (Olopatadine Hydrochloride and Mometasone Furoate Monohydrate Nasal Spray) Is Approved for Commercialization in China
The Global Innovative Product TP-03 for the Treatment of Demodex Blepharitis Is Approved for Commercialization in China
The NDA of Grand Pharma’s Global Innovative RDC TLX591-CDx Is Accepted by the NMPA
International R&D Center in Optics Valley, Wuhan
Technical Support for High-end PreparationsPHARMACEUTICAL TECHNOLOGY
NUCLEAR MEDICINE ANTI-TUMOR DIAGNOSIS AND TREATMENT AS WELL AS CEREBRO- CARDIOVASCULAR PRECISION INTERVENTIONAL DIAGNOSIS AND TREATMENT TECHNOLOGY
BIOTECHNOLOGY
23/F, Chengshi Plaza, No. 160 Qiaokou Road, Wuhan
430032
+86-400-990-9097 (Product Complaint Hotline)